Fidelis Capital Partners LLC Purchases New Shares in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

Fidelis Capital Partners LLC purchased a new position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 12,762 shares of the specialty pharmaceutical company’s stock, valued at approximately $71,000. Fidelis Capital Partners LLC owned approximately 0.10% of Eagle Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the stock. Headlands Technologies LLC increased its stake in shares of Eagle Pharmaceuticals by 75.7% during the first quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock worth $35,000 after purchasing an additional 2,861 shares in the last quarter. Vanguard Personalized Indexing Management LLC purchased a new stake in Eagle Pharmaceuticals during the 2nd quarter worth approximately $76,000. Price T Rowe Associates Inc. MD acquired a new position in shares of Eagle Pharmaceuticals during the first quarter valued at approximately $83,000. Aristides Capital LLC purchased a new position in shares of Eagle Pharmaceuticals in the fourth quarter valued at approximately $86,000. Finally, XTX Topco Ltd acquired a new stake in shares of Eagle Pharmaceuticals in the second quarter worth approximately $113,000. 85.36% of the stock is currently owned by institutional investors and hedge funds.

Eagle Pharmaceuticals Stock Down 1.6 %

Shares of NASDAQ EGRX opened at $3.90 on Tuesday. The firm has a 50-day simple moving average of $4.66 and a 200-day simple moving average of $4.70. The stock has a market capitalization of $50.58 million, a price-to-earnings ratio of 3.30 and a beta of 0.53. Eagle Pharmaceuticals, Inc. has a 52 week low of $3.21 and a 52 week high of $15.91.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on Eagle Pharmaceuticals in a research note on Wednesday, September 18th. They issued a “hold” rating for the company.

Eagle Pharmaceuticals Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.